Skip to main content

NOTICE: Due to a lapse in annual appropriations, most of this website is not being updated. Learn more.

Form submissions will still be accepted but will not receive responses at this time. Sections of this site for programs using non-appropriated funds (such as NVLAP) or those that are excepted from the shutdown (such as CHIPS and NVD) will continue to be updated.

U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Search Publications by: William Brad O'Dell (Fed)

Search Title, Abstract, Conference, Citation, Keyword or Author
Displaying 1 - 6 of 6

Development and characterization of the NISTCHO reference cell line

March 18, 2025
Author(s)
Hussain Dahodwala, Irfan Hodzic, Alexei Slesarev, Ben Cutak, Alexander Kuzin, Rahul Lal, Jiajian Liu, James Mahon, Rajagopalan Lakshmi Narasimhan, Jaya Onuska, James Ravellette, Kelsey Reger, Sadie Sakurada, Floy Stewart, Trissa Borgschulte, Colette Cote, Kelvin Lee, Zvi Kelman, William Brad O'Dell, Britta Anderson
Well characterized reference materials enable successful collaborations within the scientific community by establishing common reagents for benchmarking studies and reducing the barriers to sharing materials and information. Here, we report the development

Backbone NMR assignment of the yeast produced Fab fragment of the NISTmAb reference antibody

March 1, 2023
Author(s)
Tsega Solomon, Kinlin Chao, Genevieve Gingras, Yves Aubin, William Brad O'Dell, John Marino, Robert Brinson
The monoclonal antibody (mAb) protein class has become a primary therapeutic platform for the production of new life saving drug products. MAbs are comprised of two domains: the antigen-binding fragment (Fab) and crystallizable fragment (Fc). Despite the

Characterization of the internal translation initiation region in monoclonal antibodies expressed in Escherichia coli

October 11, 2019
Author(s)
Erik M. Leith, William Brad O'Dell, Na Ke, Colleen McClung, Mehmet Berkmen, Christina Bergonzo, Robert G. Brinson, Zvi Kelman
Monoclonal antibodies (mAbs) represent an important platform for the development of biotherapeutic products. While most mAbs are produced in mammalian cells, there are several examples of mAbs made in Escherichia coli, including therapeutic fragments. When
Was this page helpful?